Navigation Links
Data from Investigator-Sponsored Trial of Oncophage Cancer Vaccine,in Glioma Presented at American Association of Neurological,Surgeons Annual Meeting

rials. These risks and uncertainties include, among others, the risk that a small investigator-sponsored study in 12 patients is not representative of what will be shown in larger trials that could support registration; and the factors described under Factors That May Impact Future Results in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of Antigenics' Annual Report on Form 10-K as filed with the Securities and Exchange Commission on March 16, 2007. Antigenics cautions investors not to place considerable reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this document, and Antigenics undertakes no obligation to update or revise the statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Antigenics' business is subject to substantial risks and uncertainties, including those identified above. When evaluating Antigenics' business and securities, investors should give careful consideration to these risks and uncertainties.

Contact

Antigenics Inc.
Sunny Uberoi, 917-443-3325
Media Relations
suberoi@antigenics.com
or
Robert Anstey, 800-962-2436
Investor Relations
ir@antigenics.com


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
7. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
8. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
9. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
Post Your Comments:
(Date:7/22/2008)...SOUTH SAN FRANCISCO, Calif., July 22 /PRNewswire/ ...t it has completed patient enrollment,in its Phase...bility and,ammonia scavenging effects of HPN-100 (...henylbutyrate) in patients with urea cycle disorde...esults in the fourth quarter,of this year., (Logo...
(Date:7/22/2008)... Developed and Validated by Columbia University Me...Proprietary MicroRNA Technology, The Test Differ... Lung Cancer (NSCLC), Classifying Squamous-Cell C... Percent and Specificity of 90 Percent,This is the...s, Sensitivity as Biomarkers for Accurate...
(Date:7/22/2008)...SOPHIA ANTIPOLIS, France, July 22 /PRNewswire-Firs...nnounced it has successfully completed the,enrollm...olled hypertension,in two clinical pharmacology st...y announced timelines. These trials are designed t..., in comparison to ibuprofen and,naproxen, using t...
(Date:7/22/2008)...Pilot Study Suggests That Ekkyo,s New Approach of ...ally Improve Scar Healing Physiology, MARSEILLES,...nown as,Heatwave Technology) a photomedicine compa...ems for skin scar prevention and reduction, announ...in Lasers in Surgery and Medicine*,reporting the r...
Breaking Medicine Technology:Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 2Hyperion Therapeutics Completes Enrollment in Phase 1/2 Clinical Trial in Patients With Urea Cycle Disorders 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 2First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 3First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 4First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval 5NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 2NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients 3Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 2Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine" 3Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board 1975 1Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board 1975 2Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board 1975 3Evotec Appoints Mario Polywka and Klaus Maleck to the Management Board 1975 4JAMA Reports HIV Spike Among Gay Men 3B AHF Says Routine Testing Effective Prevention Needed 7071 1JAMA Reports HIV Spike Among Gay Men 3B AHF Says Routine Testing Effective Prevention Needed 7071 2JAMA Reports HIV Spike Among Gay Men 3B AHF Says Routine Testing Effective Prevention Needed 7071 3JAMA Reports HIV Spike Among Gay Men 3B AHF Says Routine Testing Effective Prevention Needed 7071 4ANDRILLs 2nd Antarctic drilling season exceeds all expectations 1359 1ANDRILLs 2nd Antarctic drilling season exceeds all expectations 1359 2ANDRILLs 2nd Antarctic drilling season exceeds all expectations 1359 3Titanium Group Announces Biometric Contract with One of the Most Active Clinics in Hong Kong 1358 1Titanium Group Announces Biometric Contract with One of the Most Active Clinics in Hong Kong 1358 2Titanium Group Announces Biometric Contract with One of the Most Active Clinics in Hong Kong 1358 3
...Maintained Stability,Significantly Longer than Pla...Comparable with Placebo , MARIETTA, Ga. and COLLEG..., Inc., Wyeth Pharmaceuticals, a division of Wyeth...tudy results on,bifeprunox, an investigational tre...enia, today at the 2007 annual meeting of,the Amer...
...ire-FirstCall/ -- Forest,Laboratories, Inc. and Cy...inary top-line results from a 1,196 patient random...d pivotal Phase III,study demonstrate statisticall...s a treatment of fibromyalgia syndrome. At this ti...tial top-line,results and further analyses will be...
Other Medicine Technology:New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 2New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 3New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 4New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 5Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 2Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 3Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 4Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 5Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce,Positive Results of Phase III Study for Milnacipran as a Treatment,for Fibromyalgia Syndrome 6
(Date:7/25/2008)...weight or obese is not only a personal issue that ...ssue that impacts other people in society. A new s...eals that the extra Medicare cost associated with ...t financial burden on tax payers, costing up to hu...rrent Medicare population. , The article,s find...
(Date:7/25/2008)...ers tips and encourages them to, ,Speak Up,(TM) f... 25 /PRNewswire-USNewswire/ -- The Pennsylvania,Pa...tient Safety Day" which,is a national effort to en... fully in their healthcare by asking questions and...or illness., "We understand the important role th...
(Date:7/25/2008)...ber of jobs created in the medical field slowed in...nt kind of slowdown: they laid off fewer people in... Seattle, WA (PRWEB) July 25, 2008 -- Thoug...slowed in June overall, pharmaceutical companies r...music to the ears of sales representatives: fewer ...
(Date:7/25/2008)... of Defense and Federal Agencies in, the executio...oenix is a, four-day, multi-agency collaborative... and local agencies with large and complex inciden...ital, ad-hoc, secure mobile communications infra...ORFOLK, Va., July 25 /PRNewswire/ -- Dataline LLC ...
Breaking Medicine News(10 mins):Health News:Patient Safety Authority Supports 'National Patient Safety Day' 2Health News:Patient Safety Authority Supports 'National Patient Safety Day' 3Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3Health News:Dataline Announces Participation in Operation Golden Phoenix 2Health News:Dataline Announces Participation in Operation Golden Phoenix 3
...enge releases a dose of nicotine and is one of the...uit smoking.// The federal government has announc...nada. The lozenges are to join nicotine patches, g...er the counter. This decision was taken because th...
...re Commission today came down heavily on senior ma...were responsible for the spread of a lethal bug// ...gets above infection control. A couple of outbrea...pital resulted in 33 deaths far more than the 12 o...
...e-up of community health care could cause a change...e been made to merge the roles of community health...t nurses into one community health job. This could...ss Scotland. These were the plans that were outli...
...shington residents have taken ill after eating raw...t of Health has reported. The Health department ha...oid eating raw shellfish. Oysters that are prope...ut raw oysters may be prone to bacteria that is fo...
Other Medicine News:Health News:"Serious Failings" Led To Spread Of Lethal Hospital Bug 2
Packed conveniently in plastic-wrapped racks of 96 tips, Sterilized Diamond- Tips are ready to useno need to autoclave. Sterilized Diamond Tips are irradiated by gamma-rays for more efficient sterili
Designed for applications that demand the utmost in biological purity, individually packed Finntip BioCon tips are endotoxin-free, DNA-free, DNase-free and RNase-free. Finntip BioCon tips are guaran
Finntips have been designed to optimize the accuracy and precision of Finnpipettes. The quality of our tip products is widely recognized by customers throughout the world. The Finntip range has been
Designed to fit a variety of 250 L and 300 ul multi-channel pipettors, this tip offers a secure fit and extra space for repeat pipetting.
Medicine Products: